NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the ...

(Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and ...

REYKJAVIK, Iceland and LONDON, UK I August 21, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of ...

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive ...

inMMyCAR is a multi-center Phase 1, open-label, dose-escalation clinical trial designed to assess the safety and preliminary efficacy of a single dose of KLN-1010. The first patient was dosed at Royal ...

AUSTIN, TX, USA I August 19, 2025 I Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class ...

Company’s second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - ...

MELBOURNE, Australia I August 21, 2025 I SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-human ...

SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other ...

CRANBURY, NJ, USA I, 2025 I Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a ...

SHANGHAI, China I August 19, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed ...